Within-visit Blood Pressure Variability in Children and Adolescents in the National Health and Nutrition Examination Survey (2013-2020)

Sandeep K Riar; Scott Gillespie; Andrew M South

doi:10.1101/2024.08.14.24312023

Abstract

Background It is assumed that BP decreases with repeat measurements and multiple readings are recommended. There is limited information about within-visit BP variability (BPV) in healthy children.

Methods We used NHANES data (2013-2020) to measure BPV in subjects 8-17 years old with three BP readings. During 2013 to 2016, auscultatory BP was obtained (manual protocol, MP). Subsequently, oscillometric BP was measured (automated protocol, AP). We excluded subjects with diastolic BP ‘zero’.

Results We included a total 5656 subjects with 3365 (59.5%) in the MP and 2291 (40.5%) in the AP group. A ΔBP (individual-level difference between the highest and lowest of three BP readings) ≥5 mmHg was noted in 49.1% and 60.7% subjects for systolic BP (SBP) and diastolic BP (DBP) respectively. A ΔDBP ≥10 mmHg and DBP average real variability ≥10 mmHg was twice as common in the MP than AP group. A ΔBP ≥20 mmHg was noted in 1.3% and 4.4% subjects for SBP and DBP respectively. The first SBP and DBP reading was ≥5 mmHg higher or lower than the averaged second and third SBP and DBP readings in 24.9% and 34.5% of subjects respectively. The first SBP and DBP reading was the highest of three BP readings in 44.2% and 42.4% subjects respectively.

Conclusions There is significant BPV in children and adolescents. Diastolic BPV is more common in MP than AP groups. Initial BP is not always the highest and inclusion of second and third BP reading may be more representative of patient’s actual BP.

Competing Interest Statement

SKR has stocks. AMS has received consulting fee (Conjupro).

Clinical Trial

We did not register with ClinicalTrials.gov as this is a descriptive study.

Funding Statement

None.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB waived the need for approval.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes